[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-neoplasm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,82,113,136,159,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053818","eeg-guided-cognitive-function-preservation-in-patients-with-brain-tumors-100053818",false,"NCT07699172","EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors","A Prospective Single-Arm Study of EEG-Based Neural Signal Decoding for Cognitive Function Preservation in Patients Undergoing Brain Tumor Surgery","Inclusion Criteria:\n\n* Age 18 years to 75 years.\n* Patients diagnosed with brain glioma and scheduled for surgical treatment.\n* Conscious and able to understand study procedures.\n* Able to complete neuropsychological assessments.\n* Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe dysfunction of major organs (heart, lung, liver, or kidney).\n* Severe psychiatric disorders or cognitive impairment.\n* Severe language impairment preventing completion of study procedures.\n* Any other condition judged by the investigator to make participation inappropriate.","ALL","18 Years","75 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor surgery. Participants will undergo standardized neuropsychological assessments together with preoperative, intraoperative, and postoperative electrophysiological recordings. The study will investigate whether EEG-based neural decoding can improve objective cognitive function assessment and support individualized functional preservation during brain tumor surgery.",[27,28,29],"Glioma","Brain Neoplasm","Brain Tumor Adult",[31,32,33,34,35,36],"Electroencephalography","EEG","Neural Signal Decoding","Cognitive Function","Cognitive Preservation","Brain Tumor Surgery","NOT_YET_RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2028-07-31",{"name":47,"class":48},"Bo Wang","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100258134","tumor-related-epilepsy-100258134","NCT02639325","Tumor Related Epilepsy","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, a candidate must meet all the following criteria:\n\n* Be 8 years of age or older.\n* Have solitary primary or recurrent brain tumor with associated seizures. Brain tumor may be diagnosed radiologically. Associated seizures are defined as those with activity starting within three months of radiologic diagnosis of the primary or recurrent tumor. In cases when the timing of seizure activity is unclear with respect to the timing of diagnosis, seizures will be considered associated with the tumor if seizure semiology is consistent with that location. Ongoing seizures are not required. Patients can be included if they have had a single previous seizure. Patients who have not experienced seizures after institution of anti-convulsant therapy are not excluded.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\n-At the time of enrollment, lack consent capacity due to cognitive impairment that would make them incapable of understanding the explanation of the procedures in this study. Cognitive capacity to consent will be determined at the time of enrollment. Patients with mental disorders or those patients who are cognitively impaired yet still retain consent capacity will not be excluded. Children may be enrolled if there is a parent or guardian able to consent on their behalf.","8 Years","99 Years",{"count":59,"type":21},100,"OBSERVATIONAL","Background:\n\nSome people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems. Researchers think this may improve the outcome for people with brain tumors. It may completely relieve or greatly reduce the number of seizures they have.\n\nObjectives:\n\nTo evaluate people with brain tumors that are associated with seizures and to offer surgical treatment. Also, to study how surgery affects seizures.\n\nEligibility:\n\nPeople age 8 and older who have a brain tumor with associated seizures. They must be willing to have brain surgery to treat their epilepsy.\n\nDesign:\n\nParticipants will be screened with a review of their medical records.\n\nParticipants will have a medical history and physical exam.\n\nParticipants will be admitted to the hospital at NIH. They will have\n\nMedical history\n\nPhysical exam\n\nNeurological exam\n\nTests of memory, attention, and thinking\n\nQuestions about their symptoms and quality of life\n\nBlood drawn\n\nThey may also have:\n\nMRI or CT scan. They will lie on a table that slides in and out of a machine that takes pictures. For part of the MRI, they will get a dye through an intravenous (IV) catheter.\n\nVideo electroencephalography monitoring. Electrodes will be placed on the scalp. The participant s brain waves will be recorded while doing normal activities. Participants will be videotaped.\n\nParticipants will keep a seizure diary before and after surgery.\n\nParticipants will have surgery to remove their brain tumor and the brain area where their seizures start.\n\nThey will stay in the hospital up to a week after surgery.\n\nParticipants have for follow-up visits at NIH.",[63,64,28],"Epilepsy","Cancer",[66,67,68,69,70],"Brain Tumor","Brain Cancer","Seizure Disorder","Seizures","Natural History","RECRUITING","2026-06-18",{"date":74,"type":41},"2026-06-22",{"date":76,"type":41},"2016-01-26",{"date":78,"type":21},"2032-07-01",{"name":80,"class":81},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":49},"100275179","phase-1-super-selective-intra-arterial-repeated-infusion-of-cetuximab-for-the-treatment-of-newly-diagnosed-glioblastoma-100275179","NCT02861898","Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma","Phase I\u002FII Trial of Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma","Inclusion Criteria:\n\n* Male or female patients of ≥18 years of age.\n* Patients with a documented histologic diagnosis of newly diagnosed glioblastoma multiforme (GBM)\n* Patients with pathology confirmed histologic EGFR overexpression\n* Patients must have at least one confirmed and evaluable tumor site.∗\n\n  \\*A confirmed tumor site is one in which is biopsy-proven. NOTE: Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within two weeks of treatment on this research study.\n* Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level of 0-2) and an expected survival of ≥ three months.\n* No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol.\n* Patients must have adequate hematologic reserve with WBC≥3000\u002Fmm3, absolute neutrophils ≥1500\u002Fmm3 and platelets ≥100,000\u002F mm3. Patients who are on Coumadin must have a platelet count of ≥150,000\u002F mm3\n* Pre-enrollment chemistry parameters must show: bilirubin\\\u003C1.5X the institutional upper limit of normal (IUNL); AST or ALT\\\u003C2.5X IUNL and creatinine\\\u003C1.5X IUNL.\n* Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL.\n* Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.\n* Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening.\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating.\n* Women of childbearing potential and fertile men will be informed as to the potential risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period.\n* Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring\n* Patients with radiological evidence of leptomeningeal disease.\n* Patients with history of allergic reaction to CTX\n* Patients who initiated or completed chemo\u002FRT",{"count":90,"type":21},33,[92,93],"PHASE1","PHASE2","Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol).\n\nThis trial will be a non-randomized open label Phase I\u002FII clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.",[96,67,28,66,97,98,99],"Glioblastoma","Brain Neoplasm, Malignant","EGFR Gene Overexpression","GBM",[101,102,103],"EGFR","Epidermal Growth Factor Receptor","EGFRvIII","2026-05-28",{"date":106,"type":41},"2026-06-01",{"date":108,"type":4},"2016-06",{"date":110,"type":21},"2029-12",{"name":112,"class":48},"Northwell Health",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":49},"100266956","electrocorticography-in-mapping-functional-brain-areas-during-surgery-in-patients-with-brain-tumors-100266956","NCT02754544","Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors","Pilot Investigation of Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Operative Functional Outcomes in Patients With Brain Tumors","Inclusion Criteria:\n\n* Patients undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed as well as recurrent primary or metastatic brain tumor located in or adjacent to motor and\u002For speech brain areas\n* Patients \\>= 18 years of age\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients with significant neurological motor deficits of the upper extremities, and\u002For speech deficits, which would preclude them from performing the while awake intra-operative tasks at the discretion of the principal investigator (PI)\n* Patients who have impaired vision and\u002For hearing and whose performance could affect the study will be excluded at the discretion of the PI",{"count":121,"type":21},75,[24],"This pilot clinical trial studies how well electrocorticography works in mapping functional brain areas during surgery in patients with brain tumors. Using a larger than the standard mapping grid currently used during brain tumor surgery or a high-definition grid for electrocorticogram brain mapping may help doctors to better identify which areas of the brain are active during specific limb movement and speech during surgery in patients with brain tumors.",[28,125,126],"Metastatic Malignant Neoplasm in the Brain","Recurrent Brain Neoplasm","2026-05-18",{"date":129,"type":41},"2026-05-20",{"date":131,"type":41},"2016-07-22",{"date":133,"type":21},"2028-01-01",{"name":135,"class":48},"M.D. Anderson Cancer Center",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":49},"100270475","phase-2-super-selective-intra-arterial-repeated-infusion-of-cetuximab-erbitux-with-reirradiation-for-treatment-of-relapsedrefractory-gbm-aa-and-aoa-100270475","NCT02800486","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed\u002FRefractory GBM, AA, and AOA","Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed\u002FRefractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma","Inclusion Criteria:\n\n* Male or female patients of ≥18 years of age\n* Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic oligoastrocytoma (AOA)\n* Patients with pathology confirmed histologic EGFR overexpression\n* Patients must have at least one confirmed and evaluable tumor site.∗\n\n  \\*A confirmed tumor site is one in which is biopsy-proven\n* Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥ three months.\n* No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol\n* Patients must have adequate hematologic reserve with WBC≥3000\u002Fmm3, absolute neutrophils ≥1500\u002Fmm3 and platelets ≥100,000\u002F mm3. Patients who are on Coumadin must have a platelet count of ≥150,000\u002F mm3\n* Pre-enrollment chemistry parameters must show: bilirubin\\\u003C1.5X the institutional upper limit of normal (IUNL); AST or ALT\\\u003C2.5X IUNL and creatinine\\\u003C1.5X IUNL\n* Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL\n* Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study\n* Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating.\n* Women of childbearing potential and fertile men will be informed of the potential unknown risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period\n* Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring\n* Patients with radiological evidence of leptomeningeal disease\n* Patients with history of allergic reaction to CTX\n* Patients who completed chemo\u002FRT less than 6 months prior to enrollment\n* Patients who have not failed standard Stupp protocol",{"count":144,"type":21},37,[93],"Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg\u002Fm2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.",[96,148,149,27,28,67,66,150,97],"Anaplastic Astrocytoma","Anaplastic Oligoastrocytoma","Brain Tumor, Recurrent","2026-04-08",{"date":153,"type":41},"2026-04-13",{"date":155,"type":41},"2016-05",{"date":157,"type":21},"2036-05",{"name":112,"class":48},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":49},"100564527","use-of-shear-wave-elastography-for-intraoperative-brain-and-tumor-stiffness-measurements-100564527","NCT06630338","Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements","Inclusion Criteria:\n\n* Patients must be at least 18 years old.\n* Patients must have planned surgery for resection of a newly diagnosed or recurrent brain tumors.\n* Patients with tumors located in the brain cortex or superficial white matter in which introduction of the ultrasound probe is straightforward and does not pose a risk for intraoperative complications.\n* Patients must have a Karnofsky performance status ≥ 60%.\n* Patient or legally authorized representative (LAR) willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with deep-seated brain tumors in which introduction of the ultrasound probe poses an increased risk.\n* Patients with a history of any brain infections.\n* Patients with implanted devices.\n* Patients with any other neurological\u002Fneurosurgical disease that could affect tissue stiffness.\n* Patients with any other structural brain defect that could affect tissue stiffness.",{"count":166,"type":21},30,"This study investigates the role of intraoperative shear wave elastography ultrasound (ISWEU) in identifying healthy brain and tumor tissue stiffness differences. This data may be used to guide tumor resection in future patients.",[66,169,28,126],"Recurrent Brain Tumor","2026-03-23",{"date":172,"type":41},"2026-03-27",{"date":106,"type":21},{"date":175,"type":21},"2033-06-28",{"name":177,"class":48},"Mayo Clinic",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":49},"100614961","non-invasive-intracranial-pressure-monitoring-in-brain-tumor-patients-100614961","NCT07286396","Non-invasive Intracranial Pressure Monitoring in Brain Tumor Patients","Non-invasive Intracranial Pressure Monitoring in Brain Tumor Patients: A Prospective Observational Study of Optic Nerve Sheath Diameter Dynamics","Inclusion Criteria:\n\n* • Adult patients (\\>21 years) undergoing brain tumor resection surgery.\n\n  * Preoperative imaging-confirmed diagnosis of the tumor.\n  * American Society of Anesthesiologists (ASA) physical status II to IV\n  * Consent to participate in the study.\n\nExclusion Criteria:\n\n* • Preexisting ocular conditions affecting the optic nerve or globe integrity, such as glaucoma, thyroid-associated ophthalmopathy, or other optic nerve diseases.\n\n  * Combined ocular and optic nerve injuries at admission.\n  * History of cranial trauma, prior neurosurgery, or lumbar puncture performed within 2 weeks before the measurement of optic nerve sheath diameter (ONSD).\n  * History of subarachnoid hemorrhage (SAH).\n  * Serious complications that could affect life expectancy, such as hematological disorders or malignancies.\n  * Refusal to participate or withdrawal of consent at any stage.","21 Years",{"count":187,"type":21},60,"This research protocol focuses on the pre- and post-operative evaluation of ICP using non-invasive methods, particularly in the context of surgery for brain tumor removal. By utilizing ocular ultrasound to measure ONSD and ONSD\u002FETD ratios, this study hypothesizes that the utility of these parameters in monitoring ICP pre- and post-operative periods could be effective.",[28,190],"Intracranial Pressure Increase","2025-12-02",{"date":193,"type":41},"2025-12-16",{"date":195,"type":21},"2026-01",{"date":197,"type":21},"2027-01",{"name":199,"class":48},"Tanta University"]